The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Open accessAbstract
Inactive state-selective KRAS(G12C) inhibitors 1-8 demonstrate a 30-40% response rate and result in approximately 6-month median progression-free survival in patients with lung cancer 9. The genetic basis for resistance to these first-in-class mutant GTPase inhibitors remains under investigation. Here we evaluated matched pre-treatment and post-treatment specimens from 43 patients treated with the KRAS(G12C) inhibitor sotorasib. Multiple treatment-emergent alterations were observed across 27 patients, including alterations in KRAS, NRAS, BRAF, EGFR, FGFR2, MYC and other genes. In preclinical patient-derived xenograft and cell line models, resistance to KRAS(G12C) inhibition was associated with low allele frequency hotspot mutations in KRAS(G12V or G13D), NRAS(Q61K or G13R), MRAS(Q71R) and/or BRAF(G596R), mirroring observations in patients. Single-cell sequencing in an isogenic lineage identified secondary RAS and/or BRAF mutations in the same cells as KRAS(G12C), where they bypassed inhibition without affecting target inactivation. Genetic or pharmacological targeting of ERK signalling intermediates enhanced the antiproliferative effect of G12C inhibitor treatment in models with acquired RAS or BRAF mutations. Our study thus suggests a heterogenous pattern of resistance with multiple subclonal events emerging during G12C inhibitor treatment. A subset of patients in our cohort acquired oncogenic KRAS, NRAS or BRAF mutations, and resistance in this setting may be delayed by co-targeting of ERK signalling intermediates. These findings merit broader evaluation in prospective clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The discovery of KRAS G12C inhibitors raises great excitement; nevertheless, intrinsic and acquired resistance to sotorasib and adagrasib has been reported in preclinical studies and clinical trials (8–10).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is believed that this resistance can arise from a variety of mechanisms, including the emergence of additional mutations in KRAS or other genes involved in the RAS pathway, non-mutational activation of bypass signaling pathways such as the MAPK or PI3K pathways, and diverse remodeling of the tumor microenvironment (8–10).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Acquired mutations of NRAS, BRAF, RTK, and MYC were also found in patients treated with sotorasib or adagrasib monotherapy [49, 51, 53, 54].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Amplifications or gene fusions of MET, EGFR, FGFR2, FGFR3, and ALK have been detected in patients with acquired resistance to sotorasib and adagrasib monotherapy [49, 51].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Expression of the identified KRAS mutants was sufficient to confer resistance to KRAS G12C inhibitors in KRAS G12C cancer cells [49, 51, 60].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [51]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therapeutic pressure from KRAS inhibition can rapidly reshape tumor clonal architecture [35,36,47,81].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Combination strategies targeting KRAS G12C and upstream regulators or downstream effectors of the RAS signaling have been extensively explored to overcome resistance to sotorasib or adagrasib (9–12, 56).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cells containing mutations conferring KRASi resistance are frequently clonally or subclonally selected and can come to dominate much of the tumor post-relapse [62,68,97].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [97]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, some of the treatment-emergent KRAS secondary mutations that are not commonly observed in primary tumors, such as KRAS V8L and KRAS V14I, arise in patients who are relatively responsive to sotorasib (as defined by RECIST scores ≤ 30) [97].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [97]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In patient tumors with KRAS G12C that were analyzed post-sotorasib treatment, 14% of tumors displayed an additional or alternative point mutation in KRAS [97].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [97]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Point mutations in the KRAS gene included G12D/F/R/V/W, which prevent covalent interactions with mutant cysteine, as well as V8L, G13D, V14I, Q61H, H95D/Q/R, Y96C, and Y96D [62,97,102,103].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [97]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many of the novel mutations were observed at low subclonal frequencies, contributing to tumor heterogeneity [97,103].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [97]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CRISPR screens specifically investigating sotorasib resistance identified and validated ERK1/2, SHOC2, NRAS, CRAF, and BRAF as vulnerable targets that were synthetically lethal with KRAS inhibition [97].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [97]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The downstream effectors of KRAS signaling that were mutated post-KRAS inhibition included activating lesions in PIK3CA, MEK1, BRAF, and RAF1 [51,68,97,112].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [97]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These included ALK, APC, CDKN2A/B, CTNNB1, IDH1/2, KEAP1, MET, MYC, NRAS, PTCH1, PTEN, RB1, RET, RICTOR, SMARCA4, and TP53 [50,97,102].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [97]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple mechanisms of acquired resistance have been identified, which largely converge on re-activation of the RAS pathway or alternatively activate parallel signaling pathways such as the PI3K/mTOR pathway10–14.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and others have recently described mechanisms of acquired resistance in patients with lung and colorectal cancer (CRC) treated with KRASG12C inhibitors, including mutations in KRAS or other RTK–RAS–MAPK pathway effectors, adaptive signaling alterations, and histologic transformation to drug-resistant cell states (14, 18–24).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies using preclinical models have indicated that acquired resistance to KRASG12C inhibition may be mediated by the activation of multiple receptor tyrosine kinase (RTK) regulators, including epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), insulin-like growth factor 1 receptor (IGF1R), human epidermal growth factor 2 (HER2), and Src homology 2 domain-”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vertical reactivation of the RAS pathway elements has been observed in most samples collected from patients who developed resistance to KRASG12C inhibitors.4,8,20,21”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“One major route leading to such recovery of RAS activity is the activation of RTKs through either genetic (e.g., gene amplification or fusion) or non-genetic mechanisms.2,4,5,6,7,8,22,23,24,25”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A genome-wide CRISPR screen revealed that the adenosine triphosphate binding cassette transporter ABCC1 mediates MRTX849 resistance.”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This screen identified ABCC1 as a top-ranked gene whose disruption could reverse resistance to the G12Ci AMG510 (Fig. 2F).”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic alterations, especially secondary RAS mutations, have been identified as one of the most common mechanisms of acquired resistance to KRAS inhibitors in patients [49, 51–55].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, clinical efficacy remains limited by intrinsic and acquired resistance, adaptive pathway reactivation, and tumor heterogeneity.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The co-evolution of multiple putative drug-resistance mechanisms within the same tumors mirrors observations in human samples whereby multiple distinct mechanisms have been observed within the same patients (14, 18, 19).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Although this is an important milestone in precision oncology, G12Ci treatments are facing challenges due to the emerging development of drug resistance (13, 14).”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Analysis of matched pre- and post-treatment specimens from 43 (36 NSCLC, 3 CRC, and 4 other) sotorasib-treated patients revealed treatment-induced genetic alterations in 27 patients, including 4 with secondary KRAS mutations (G12D, G12V, G12F, V8L) and 3 with copy-number gains of KRAS [51].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Long-term culture in high-dose adagrasib (10 × IC50) was used to generate adagrasib-resistant NCI-H358 cells (NCI-H358R), which were confirmed to retain KRASG12C and did not acquire any mutations associated with resistance in patients9,11 (Supplementary Table 10).”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“In a study of sotorasib-treated patients, 7% of patients in the study developed KRAS G12C amplifications [97].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“Time courses of G12C-mutant cell lines treated with increasing doses of G12C inhibitors demonstrated that the population frequency of rare resistance mutations increased over time [97].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“While previous studies have characterized acquired resistance to KRASG12C inhibition and identified causal mutations and non-genetic mechanisms including RTK activation and epithelial-to-mesenchymal transition11–14,35, the mechanisms underlying differential sensitivity to KRASG12C inhibition are less well understood.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [14]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous reports have shown that PIK3CA mutations can confer acquired resistance to KRAS G12C inhibitor and KRAS G12C inhibitor–cetuximab combination therapy in patients with NSCLC and CRC34–36.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [34]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“sgRNAs against CAB39, DUSP4, and NRBP1 were enriched in sotorasib-resistant cells, suggesting that their loss confers a selective advantage during treatment [97].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [97]
Experimental — accuracy not yet measuredIn the citing paper
“Nonetheless, there remains an ongoing need for improved clinical outcomes (21), especially since emerging data indicate multiple mechanisms of acquired resistance in patients treated with sotorasib or adagrasib (22–24), many of which involve RAS pathway reactivation.”
In the citing paper
“Despite this success, disease progression occurs in many patients4,5,7, with development of resistance to KRASG12Ci recapitulated in preclinical studies9–11.”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [11]
In the citing paper
“Transcriptomic analysis of tumors explanted at the end of study, however, did not identify secondary KRAS mutations, increased KRAS expression, or genomic aberrations, previously reported in tumors with acquired resistance to KRASG12Ci (refs. 9,11) (Supplementary Table 12).”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [11]
In the citing paper
“Many of the aforementioned mutations were detected only at low frequencies and only in approximately half of patients relapsing on KRASG12Ci (ref. 11).”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [11]
In the citing paper
“activating mutations in MRAS (Q71R) have been reported at low allelic frequency in KRASG12Ci-resistant NSCLC cell lines11.”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [11]
In the citing paper
“Pan-KRAS drugs would have advantages versus mutant-selective KRAS drugs in heterogeneous cancers driven by multiple KRAS alterations at baseline or upon development of acquired resistance due to secondary KRAS on-target alterations when compared to mutant-selective inhibitors (Fig. 3), with first examples emerging in the clinic (64–66).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Self-citationK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Self-citationMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citation
Cited by
Sorted by citations
Items 201–300 of 476
Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers
Chareddy, Y. S., Huggins, H. P., Sahoo, S. S., Stanland, L. J., Gutierrez-Ford, C., Whately, K. M., Edatt, L., Azam, S. H., Fleming, M. C., Im, J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci187204 · Cited by 11
Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions
Peng, C., & Oberstein, P. E. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01352-2 · Cited by 14
Solanki, H. S., Shah, H., Imbody, D. J., Desai, B., Kato, R., Miroshnychenko, D., Stern, Y. E., Majumder, A., Sarcar, B., Xieraili, A., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0600 · Cited by 10
Stahlhut, C. E., Maciag, A. E., Sullivan, K. A., Singh, K., Gitego, N., Zhang, Z., Chan, A. H., Sharma, A. K., Alexander, P., Shu, J., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1280 · Cited by 10
McAndrews, K. M., Mahadevan, K. K., Li, B., Comptdaer, A. M., Sockwell, A. M., Morse, S. J., Kelly, P. J., Patel, S. I., Kirtley, M. L., Diaz, B. A. M., et al. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00854-5 · Cited by 10
Self-citationOvercoming MET-mediated resistance in oncogene-driven NSCLC
Reischmann, N., Schmelas, C., Molina‐Vila, M. Á., Jordana‐Ariza, N., Kuntze, D., García-Román, S., Simard, M. A., Musch, D., Esdar, C., Albers, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107006 · Cited by 10
Assessment of KRASG12C inhibitors for colorectal cancer
Piazza, G. A., Chandrasekaran, P., Maxuitenko, Y. Y., & Budhwani, K. I. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1412435 · Cited by 11
Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors
Arbour, K. C., & Lito, P. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00562 · Cited by 10
Self-citationDNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer
Chiou, L.-W., Chan, C.-H., Jhuang, Y., Yang, C., & Jeng, Y. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00940-4 · Cited by 10
YAP and TAZ orchestrate adaptive resistance to KRAS inhibitors
Mira, A., & Ambrogio, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00580-5 · Cited by 10
Liu, H., Zhou, C., Lü, J., Liu, Y., Zou, P., Zhu, L., Lei, H.-M., & Han, B. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07687-w · Cited by 9
Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?
Cartwright, D., Kidd, A. C., Ansel, S., Ascierto, M. L., & Spiliopoulou, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094393 · Cited by 9
Passiglia, F., Pepe, F., Russo, G., Garbo, E., Listì, A., Benso, F., Scimone, C., Palumbo, L., Pluchino, M., Minari, R., et al. (2025) · Cancer · doi:10.1002/cncr.35917 · Cited by 9
Hibshman, P. S., Stalnecker, C. A., Klomp, J. A., Drizyte‐Miller, K., Klomp, J. E., Edwards, A. C., Pita, L. M., Hodge, R. G., Diehl, J. N., Mouery, R. D., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adu7145 · Cited by 9
AZD4625 is a Potent and Selective Inhibitor of KRASG12C
Chakraborty, A., Hanson, L. L., Robinson, D. M., Lewis, H. J., Bickerton, S., Davies, M., Polański, R., Whiteley, R., Koers, A., Atkinson, J. M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0241 · Cited by 9
Bhamidipati, D., & Subbiah, V. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101591 · Cited by 10
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
Cheema, P. K., Banerji, S. O., Blais, N., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., Sacher, A. G., Sheffield, B. S., Snow, S. L., Vincent, M. D., et al. (2023) · Current Oncology · doi:10.3390/curroncol30070476 · Cited by 10
Luo, W. P., Zhu, J., Zhang, W., Yu, A., Zhou, W., & Xu, K. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2282606 · Cited by 10
Protein tyrosine phosphatases: emerging role in cancer therapy resistance
Zhao, M., Shuai, W., Su, Z., Xu, P., Wang, A., Sun, Q., & Wang, G. (2024) · 癌症：英文版 · doi:10.1002/cac2.12548 · Cited by 9
López-Estévez, A. M., Sanjurjo, L., Turrero, Á., Arriaga, I., Abrescia, N. G. A., Poveda, A. M., Jiménez‐Barbero, J., Vidal, A., Torres, D., & Alonso, M. J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.032 · Cited by 9
Inhibitors of the GTPase KRASG12Cin cancer: a patent review (2019-2021)
Xu, Q., Zhang, G., Liu, Q., Li, S., & Zhang, Y. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2032648 · Cited by 9
Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer
Guo, M. Z., Marrone, K. A., Spira, A. I., & Rosner, S. (2023) · Future Oncology · doi:10.2217/fon-2022-1106 · Cited by 10
KRAS takes the road to destruction
Cox, A. D., & Der, C. J. (2024) · Science · doi:10.1126/science.ads2150 · Cited by 9
Advances in RAS Therapeutics for Pancreatic Cancer
Der, C. J., & Yeh, J. J. (2026) · New England Journal of Medicine · doi:10.1056/nejme2600517 · Cited by 9
Identification of USP2 as a novel target to induce degradation of KRAS in myeloma cells
Wang, Y., Zhang, Y., Luo, H., Wei, W., Liu, W., Wang, W., Wu, Y., Peng, C., Ji, Y., Zhang, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.08.019 · Cited by 8
Spatial immunogenomic patterns associated with lymph node metastasis in lung adenocarcinoma
Meng, F., Li, H., Jin, R., Yang, A., Luo, H. L., Li, X., Wang, P., Zhao, Y., Chervova, O., Tang, K., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00574-8 · Cited by 8
Self-citationConn, B. P., Dietze, J. L., Yee, C. J., Hallisey, M., Ortiz-Caraveo, I., van Buuren, M. M., Gaynor, R. B., Foley, K. C., Choi, J., & Juneja, V. R. (2025) · Cell Reports Methods · doi:10.1016/j.crmeth.2025.101049 · Cited by 9
Baird, L., Zhang, L., Hidaka, T., Xi, L., Wang, K., Tateno, K., Iso, T., Suzuki, T., Kumada, K., Katsuoka, F., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03162-7 · Cited by 10
Jia, R. F., Xiao, C., Zhang, Y., Hu, L.-Y., Jun-jun, Y., Zuo, R., Hu, Y., Xie, Y.-H., Ma, X., Li, Q., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101311 · Cited by 8
Alanazi, F. E., Alatawi, Y. M., Alattar, A., Alshaman, R., Kotb, A. A., & Hetta, . F. (2025) · Pharmaceuticals · doi:10.3390/ph18121788 · Cited by 8
Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C
Condakes, M. L., Zhang, Z., Danahy, D. B., Moore, R. R., Lakkaraju, S. K., Zhuo, X., Amako, Y., Borzilleri, R. M., Balachander, S. B., Chourb, L. S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69003-0 · Cited by 8
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer
Alonso, S., Chu, K., Granowsky, E., Saraiba-Rabanales, V., Parsons, M. J., Gunasinghe, H. I., Shia, J., Yaeger, R., & Dow, L. E. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.04.009 · Cited by 8
TargetingKRAS G12Cmutations in colorectal cancer
Zhao, M., & Wu, A. (2022) · Gastroenterology report · doi:10.1093/gastro/goac083 · Cited by 9
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
Brazel, D., Kim, J., & Ou, S. I. (2023) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s403614 · Cited by 8
New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer
Janssens, K., Lambrechts, C., Geerinckx, B., de Beeck, K. O., Camp, G. V., Oliveres, H., Prenen, H., Vandamme, T., & Peeters, M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01095-y · Cited by 9
Insights into how adeno-squamous transition drives KRAS inhibitor resistance
Hu, F., & Lito, P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.014 · Cited by 8
Self-citationDual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
Novoplansky, O., Jagadeeshan, S., Prasad, M., Yegodayev, K. M., Marripati, D., Shareb, R. A., Greenshpan, Y., Mathukkada, S., Lulu, T. B., Bhattacharya, B., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03227-0 · Cited by 8
Nakazawa, S., Pecci, F., Ricciuti, B., Gottlieb, F. H., Facchinetti, F., Harada, G., Chen, M. F., Repetto, M., Giacomini, F., Jiang, J., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.03.045 · Cited by 8
Zhang, L., Sun, S., Zhao, X., Liu, J., Xu, Y., Xu, L., Song, C., Li, N., Yu, J., Zhao, S., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13297 · Cited by 8
Self-citationGorachinov, F., Mraiche, F., Moustafa, D. A., Hishari, O., Ismail, Y., Joseph, J. M., Crcarevska, M. S., Dodov, M. G., Geškovski, N., & Goračinova, K. (2023) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.14.23 · Cited by 8
The KRYSTAL-1 study of adagrasib — a new trial for KRASG12C-mutated non-small-cell lung cancer
Murciano‐Goroff, Y. R., & Lito, P. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00676-4 · Cited by 8
Self-citationDifferential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
SRC at the Crossroads of KRAS Inhibitor Resistance: Mechanisms and Therapeutic Opportunities
Tian, H., Zhao, D., Zhou, Z., Kim, A., Huang, H., Lee, Y. J., Qu, Z., Kang, R., Zeh, H. J., Westover, K. D., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2025.218194 · Cited by 7
Live-cell target engagement of allosteric MEKi on MEK–RAF/KSR–14-3-3 complexes
Marsiglia, W. M., Chow, A., Khan, Z. M., Liu, H., & Dar, A. C. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01454-8 · Cited by 7
KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review
Tang, M., Wu, Y., Bai, X., & Lü, Y. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s473368 · Cited by 7
Alva‐Ruiz, R., Watkins, R. D., Tomlinson, J. L., Yonkus, J. A., Abdelrahman, A. M., Conboy, C. B., Jessen, E., Werneburg, N. W., Kuipers, H., Sample, J. W., et al. (2024) · FEBS Open Bio · doi:10.1002/2211-5463.13901 · Cited by 7
Zeng, J., Jiang, W., & Wu, L. (2025) · Journal of Translational Research · doi:10.1080/29947448.2024.2427647 · Cited by 7
The ubiquitin code of RAS proteins: Decoding its role in cancer progression
Shi, Y., Shen, Y., Zhang, X., Zhu, N. W., Ding, Y., Yuan, Y., & Wang, J. (2025) · iScience · doi:10.1016/j.isci.2025.113029 · Cited by 7
Targeting KRAS in colorectal cancer (Review)
Zhang, M., Wu, D., Tang, C. Y. L., Zhang, L., Zhang, S., Li, W., Li, N., & Yan, X. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2873 · Cited by 9
Integrative genomic identification of therapeutic targets for pancreatic cancer
Guo, J. A., Gong, D. H., Evans, K. E., Takahashi, K., Jambhale, A. D., Shiau, C., Yu, P. Z., Wang, S., Wu, W., Chugh, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116191 · Cited by 9
Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Wang, L., Wei, D., Li, S., & Jiang, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-03569-x · Cited by 7
Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors
Stern, Y. E., Ghosh, P., Peroza, J., Solanki, H. S., Imbody, D. J., Bridenstine, L., Pandurangan, T., Frydman, S. M., Nickens, K. N., Walker-Mimms, H. L., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0450 · Cited by 7
Identification and characterization of binders to a cryptic and functional pocket in KRAS
Beyer, K. S., Klein, J., Katz, S., Welker, P., Lanter, M., Guthy, D. A., Pollehn, K., Gluck-Gadé, A., Bleu, M., Desogus, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65844-3 · Cited by 7
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C
Endres, N., Do, S., Mroue, R. M., Terrett, J. A., Saabye, M., Oh, A., Hunsaker, T., Chan, E., (1471192), J. C. T., Nguyen, L. K., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02272 · Cited by 8
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors
Mouti, M. A., & Pauklin, S. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.004 · Cited by 7
Jameson, N. M., Kim, D., Lee, C., Skrable, B., Shea, A., Guo, X., Izadi, H., Abed, M., Harismendy, O., Ma, J., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0411 · Cited by 7
Self-citationPrimary refractory plasmablastic lymphoma: A precision oncology approach
Witte, H. M., Fähnrich, A., Künstner, A., Riedl, J., Fliedner, S. M. J., Reimer, N., Hertel, N., von Bubnoff, N. C. C., Bernard, V., Merz, H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1129405 · Cited by 7
Guo, C., Deng, H., Yang, Q., Huang, D., Shen, C., Wang, G. A., & Li, F. (2023) · Angewandte Chemie · doi:10.1002/ange.202314386 · Cited by 7
Theardy, M. S., Takeda, M., Sorokin, A., Chen, S., Yang, Z., Wang, X., Kanikarla, P., Coker, O., Nguyen, P., Wei, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102253 · Cited by 6
Gong, Z., Zhao, Y., Xu, B., Zhou, Y., Ren, B., Yang, H. B., Zeng, C., Chen, R., Xu, Y., & Li, Q. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106954 · Cited by 6
Self-citationBonsor, D. A., Finci, L. I., Potter, J. R., Young, L. C., Wall, V. E., de Salazar, R. G., Geis, K. R., Stephens, T., Finney, J., Nissley, D. V., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68319-1 · Cited by 6
Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC
Ortiz‐Cuaran, S., Dupriez, L., Nicq, C., Lindsay, C. R., Mazières, J., Santamarı́a, D., Ambrogio, C., Calvayrac, O., Teixidó, C., Friboulet, L., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.12.001 · Cited by 6
Huang, R., Gong, X., Du, J., Xu, G., Qian, J., Liao, G., Lin, Y., Pan, M., Zheng, B., Yuan, W., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1704347 · Cited by 6
Wei, X., Blaj, C., Al-Radhawi, M. A., Lai, L., Maldonato, B. J., Yang, Y. C., Seu, L., Gundlapalli, H., Jiang, L., Ayala, M. A. M., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1616 · Cited by 6
Lin, Q., Morales-Giron, A. A., Sander, C., Curtis, J. M., Barnes, H., Patel, P. S., de la Cruz, F. F., Riedl, J. M., Matsubara, H., Nakamura, H., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1788 · Cited by 6
Alisertib exerts KRAS allele‑specific anticancer effects on colorectal cancer cell lines
Ren, B., 高卓维, Zheng, K., Yang, Y., Su, P., Luo, Q., Feng, J., Zhentao, L., Geng, Y., Ju, Y., et al. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11942 · Cited by 6
Cheng, F., Li, P., Xu, S., Zhang, C., Liang, H., & Ding, Z. (2024) · Aging · doi:10.18632/aging.205595 · Cited by 5
Hindul, N. L., Abbott, L. R., Adan, S. M. D., Straatman, K. R., Fry, A. M., Hirota, K., & Tanaka, K. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107409 · Cited by 6
The expression and functional role of proline-rich 15 in non-small cell lung cancer
Ji, Y. H., Zhang, H., Gong, F.-L., Liang, J.-W., Wang, S.-F., Sang, Y., & Zheng, M.-F. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07373-x · Cited by 6
Chen, P., Huang, B. J., Harris, M., Boone, C. D., Wang, W., Carias, H., Mesiona, B., Mavrici, D., Kohler, A. C., Bollag, G. E., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.168445 · Cited by 6
Combinatorial approaches for mitigating resistance to KRAS-targeted therapies
Warren, H. R., Ross, S. J., Smith, P. D., Coulson, J. M., & Prior, I. A. (2022) · Biochemical Journal · doi:10.1042/bcj20220440 · Cited by 6
Acquired resistance of cancer therapies: Mechanisms and perspectives
Wang, M., Zhai, X., Li, J., Chen, J., Gai, X., Liu, X., Liu, Y., Zhou, Q., & Chen, C. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004048 · Cited by 5
Foth, M., Kim, W., O’Toole, K. T., Murphy, B., Justo-Garrido, M., Boggaram, S. S., Ghazi, P. C., Brennan, E., Wright, M. I., Shepherd, T., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-26-1313 · Cited by 5
Farnesylation-driven KRAS phase separation promotes colon tumor growth
Wang, X., Zhang, Y., Lu, M., Gong, Y., Guan, T., Hou, G., Wei, Y., Wang, M., Liu, H., Huang, L., et al. (2026) · Cell · doi:10.1016/j.cell.2026.05.002 · Cited by 5
Rosas, D., Barad, P., Wright, J., & Raez, L. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146455 · Cited by 5
Analysis of the immune microenvironment in colorectal cancer with different KRAS gene subtypes
Huang, J., Gong, Q., Li, Q., Xiao, M., Li, M., Zhang, S., Wang, Y., & Tang, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-14660-5 · Cited by 5
Self-citationKRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer
Wei, Y., Liu, M., Yen, E.-Y., Yao, J., Xun, Z., Nguyen, P. T.-M., Wang, X., Yang, Z., Yousef, A. M. G., Pan, D. N., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-2024 · Cited by 5
Self-citationDriver and targetable alterations in Chinese patients with small bowel carcinoma
Li, J., Li, X., Dong, N., Shu, Y., Jing, C., Ma, T., Li, W., Zhang, C., Cai, Y., & Deng, W. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04521-0 · Cited by 5
KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer
Xiao, A., & Fakih, M. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.05.004 · Cited by 5
Targeting active RAS with molecular glue
Su, W., & Hou, X. (2024) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2024.100047 · Cited by 5
Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer
Dekker, S. E., & Deng, L. (2024) · Cancers · doi:10.3390/cancers16223885 · Cited by 5
Zhang, J., Zhang, J., Leung, E. L., & Yao, X. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2178419 · Cited by 5
Unconventional strategy could be the future: From target to KRAS broad range treatment
Fancelli, S., Petroni, G., Pillozzi, S., & Antonuzzo, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29739 · Cited by 6
Understanding and drugging RAS: 40 years to break the tip of the iceberg
Brady, D. C., Hmeljak, J., & Dar, A. C. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049519 · Cited by 5
Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers
Cox, A. D., Ting, J. P. ‐., & Der, C. J. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1199 · Cited by 5
Discovery of RMC-6291, a potent, orally bioavailable, covalent RAS(ON) G12C selective inhibitor
Cregg, J., Pota, K., Gill, A. L., & Koltun, E. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00006-1 · Cited by 4
The RAS Signaling Network and Cancer
Hibshman, P. S., & Der, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_17 · Cited by 4
An overview of PROTACs targeting KRAS and SOS1 as antitumor agents
Han, Z., Wu, Q., Rao, H., Xu, T., & Zhou, C. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130283 · Cited by 5
Escher, T. E., Yuk, S. A., Yuan, Q., Qiang, W., Almunif, S., Sharma, S., Scott, E. A., & Satchell, K. J. F. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00179 · Cited by 4
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma
Entrialgo‐Cadierno, R., Morali, K., Feliu, I., Wang, Y., Evans, J., Yáñez-Bartolomé, M., López, I., Macaya, I., Cueto‐Ureña, C., Sin-Coscujuela, D., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.03.020 · Cited by 4
Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here
May, M. S., Park, W., & O'Reilly, E. M. (2026) · Drugs · doi:10.1007/s40265-026-02295-0 · Cited by 4
PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Ge, X., Singh, J., Li, W., Bishop, C. S., Ruiz, C. F., Stites, E. C., Bhattacharyya, M., Liu, Y., & Muzumdar, M. D. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3625 · Cited by 4
Schüler, M., Hense, J., Darwiche, K., Michels, S. Y. F., Hautzel, H., Kobe, C., Lueong, S., Metzenmacher, M., Herold, T., Zaun, G., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266979 · Cited by 4
Chen, S., Dong, R., Li, Y., Zheng, N., Peng, G., Lu, F., Qiu, Q., Wen, H., Wang, Y., Wu, H., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.918159 · Cited by 4
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity
Freed-Pastor, W. A., & Aguirre, A. J. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.018 · Cited by 4
Mullaguri, S. C., Akula, S., Sahoo, P. S., Ashireddygari, V. R., Mupparapu, V., Silveri, R., Burra, P. V. L. S., & Kancha, R. K. (2022) · 3 Biotech · doi:10.1007/s13205-022-03407-9 · Cited by 4
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)
Dehem, A., Mazières, J., Chour, A., Guisier, F., Ferreira, M., Boussageon, M., Girard, N., Moro‐Sibilot, D., Cadranel, J. L., Zalcman, G., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107393 · Cited by 4
KRAS degradation averts PDAC chemoresistance
Leonhardt, L., & Hebrok, M. (2024) · Nature Cancer · doi:10.1038/s43018-023-00708-7 · Cited by 4
Engineered protein circuits for cancer therapyPreprint
Lu, A. C., Moeller, L., Moore, S., Ho, K., Tobin, V., Qiang, A., Zhang, E., Li, Z., Wang, M., Xia, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.16.647665 · Cited by 5
Analysis of Pan-Specific Inhibitors of Oncogenic Mutant Forms of KRAS GTPase
Eliseev, I. A., Shkil, D. O., Shumakova, V. S., Chernyshov, V. V., Balakin, K. V., & Ivanov, R. A. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673372217250515031136 · Cited by 3
Metadata
- Authors
- Zhao, Y., Murciano-Goroff, Y. R., Xue, J. Y., Ang, A., Lucas, J., Mai, T. T., Da Cruz Paula, A. F., Saiki, A. Y., Mohn, D., Achanta, P., Sisk, A. E., Arora, K. S., Roy, R. S., Kim, D., Li, C., Lim, L. P., Li, M., Bahr, A., Loomis, B. R., de Stanchina, E., Reis-Filho, J. S., Weigelt, B., Berger, M., Riely, G., Arbour, K. C., Lipford, J. R., Li, B. T., & Lito, P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Amgen (United States) (US)
- Corresponding author
- Lito, Piro
- ORCID
- Venue
- Nature
- Published
- 2021-11-10
- Volume
- 599
- Issue
- 7886
- Pages
- 679-683
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8887821
- OpenAlex
- W3212888956
- Cited by
- 479
- References
- 31
- Citations by year
- 2026: 95 · 2025: 90 · 2024: 127 · 2023: 99 · 2022: 65 · 2021: 3
- FWCI
- 47.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000457, U54OD020355, UL1TR001873)
- National Cancer Institute (R01CA230267, K08CA191082, R01CA087486, F30CA232549, P50CA247749, P30CA008748, R01CA230745)
- National Institute of General Medical Sciences (T32GM007739)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- KRAS G12C inhibitors, sotorasib, acquired drug resistance, lung cancer, RAS mutations, BRAF mutation, ERK signaling, subclonal evolution, patient-derived xenografts, single-cell sequencing, KRAS G12V, NRAS Q61K, FGFR2, EGFR, c-Myc
- MeSH terms
- Acetonitriles, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cell Line, Female, Humans, Membrane Proteins, Mutation, Neoplasms, Piperazines, Pyridines, Pyrimidines, Cohort Studies, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, GTP Phosphohydrolases, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
